Biogen Idec (NASDAQ: BIIB) had its price target upped by Morgan Stanley from $170.00 to $177.00 in a research note released on Monday morning.

Biogen Idec traded up 0.06% on Monday, hitting $176.15. Biogen Idec has a 1-year low of $118.52 and a 1-year high of $176.47. The stock’s 50-day moving average is currently $162.0. The company has a market cap of $41.626 billion and a price-to-earnings ratio of 30.56.

A number of other analysts have also recently weighed in on BIIB. Analysts at TheStreet reiterated a buy rating on shares of Biogen Idec in a research note to investors on Friday, March 8th. Separately, analysts at Bank of America raised their EPS on shares of Biogen Idec in a research note to investors on Thursday, February 28th. They now have a neutral rating and a $177.00 price target on the stock. Finally, analysts at Canaccord Genuity upgraded shares of Biogen Idec from a hold rating to a buy rating in a research note to investors on Wednesday, February 27th. They now have a $187.00 price target on the stock, up previously from $163.00.

Fifteen equities research analysts have rated the stock with a buy rating, one has given an overweight rating, and fourteen have given a hold rating to the company. The company presently has an average rating of overweight and a consensus target price of $175.74.

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.